Introduction {#s1}
============

Esophageal cancer is a common malignant tumor of digestive tract. The incidence of esophageal cancer is eighth in all tumors and sixth in fatal cancer ([@B1]). EAC is one of the most common histological types of esophageal cancer ([@B2], [@B3]) and has increased markedly in Western countries in recent decades ([@B4], [@B5]). Esophagectomy with the addition of perioperative chemotherapy or chemoradiotherapy had improved prognosis of EAC ([@B6]--[@B8]), however not all EAC patients got cured. The use of molecularly targeted agents are not satisfied so far for EAC and it has lagged behind other cancers ([@B9]). Therefore, it is necessary to identify new predictive and prognostic biomarkers for EAC patients to improve clinical outcome.

The expression of genes has been shown to guide the prognosis of cancer patients ([@B10]). Three genes *DKK3, TXNIP*, and *CTO1* have been reported as prognosis biomarkers in EAC patients ([@B11]--[@B13]). However, these biomarkers need independent further validation to increase their sensitivity and specificity before clinical application. The advanced bioinformatic methods and resources have been developed for breast cancer, bladder cancer, esophageal squamous cell carcinoma, leiomyosarcoma, and lung cancer to analyze the prognostic abilities of genes ([@B14]--[@B19]), and greatly facilitate the development of cancer prognostic biomarkers. However, there is a lack of prognostic analysis system for EAC.

In this study, an online prognostic analysis tool for EAC was developed. It can not only rapidly evaluate the value of prognostic molecular biomarkers, but also provide the opportunities to identify the potential new therapeutic targets for EAC patients.

Materials and Methods {#s2}
=====================

Data Collection
---------------

Three EAC datasets were collected from GEO (<http://www.ncbi.nlm.nih.gov/geo/>) and TCGA (<http://cancergenome.nih.gov>), these datasets include gene expression profiles and clinical follow-up information of EAC ([Table 1](#T1){ref-type="table"}).

###### 

Datasets used in OSeac.

  ------------------------------------------------------------------------------------------
  **Dataset**   **Platform**   **Stage**\              **References**   **No. of samples**
                               **(%I/II/III/IV/NA)**                    
  ------------- -------------- ----------------------- ---------------- --------------------
  TCGA          RNAseq         11.25/27.5/33.75/\      ([@B20])         80
                               6.25/21.25                               

  GSE13898      GPL6102        15.71/34.29/10.00/\     ([@B21])         70
                               0.00/40.00                               

  GSE19417      GPL4372        --                      ([@B22])         48
  ------------------------------------------------------------------------------------------

Development of OSeac
--------------------

The OSeac server is developed as we previously described ([@B17]--[@B19]), and hosted in a windows server and adopts Appache Tomcat as web application server. Use HTML and JSP for the front end page and server side code is compiled to Java. The R package "Rserve" as a middleware enables Java to call programs written in R language. The SQL Server database is used as backend database which stores data of the gene expression profiles and clinical information. The central server for OSeac can be accessed at <http://bioinfo.henu.edu.cn/EAC/EACList.jsp>.

Results {#s3}
=======

OSeac Establishment and Usage
-----------------------------

We collected gene expression profiles and clinical follow-up information of 198 EAC patients from TCGA and GEO databases, and established OSeac to measure the association between a queried gene and patient outcome by Kaplan Meier plot. Before performing analysis, users can set up filter conditions by confounding clinical factors such as stage and gender. Four outcome terms including overall survival (OS), disease specific survival (DSS), disease-free interval (DFI) ([@B23]), and progression-free interval (PFI) ([@B23]) can be determined in OSeac.

OSeac provides the main functions that evaluate the prognostic value of gene of interests. When users input official gene symbol in the textbox, select an individual dataset or combined datasets \[the combined datasets mean that all the patients from individual datasets were combined as a pool after they were stratified into subgroups (high vs. low) based on the expression level of inputted gene in each dataset\], then choose an appropriate cutoff value for gene expression (including median, quartile or 30%) and click the "Kaplan-Meier plot" button, the server will generate survival curves and display HR with 95% confidence intervals and *P*-value on the output web page. Currently, five clinical factors were set as optional factors to limit the analysis in a subgroup of EAC patients for special needs from different researchers, these clinical factors include TNM stage, gender, race, grade and treatment response.

Validation of Previously Published EAC Biomarkers in OSeac
----------------------------------------------------------

We evaluated three published prognostic biomarkers, including *DKK3, CDO1*, and *TXNIP* ([Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}) in OSeac. As shown in [Table 2](#T2){ref-type="table"} and reported in original literatures, the higher expression of gene *TXNIP* in EAC patients implies a significant better overall survival rate, whereas higher expression of other two genes predict a significant worse overall survival. This result shows the validity and reliability of OSeac in determining the prognostic potency of genes of interests.

###### 

Performance of previously published prognostic biomarker in OSeac.

  **Gene symbol**   **Literature data**   **OSeac data**                                                             
  ----------------- --------------------- ---------------- ------ ---------- ------------------------- -------- ---- ---
  *DKK3*            116                   \<0.0500         Poor   ([@B11])   2.8012 (1.2033--6.5212)   0.0169   OS   √
  *TXNIP*           228                   0.0020           Good   ([@B12])   0.3698 (0.1424--0.9538)   0.0396   OS   √
  *CDO1*            38                    0.0360           Poor   ([@B13])   3.3329 (1.5175--7.3202)   0.0027   OS   √

*OS, overall survival; HR, hazard ratio; CI, confidence interval; DKK3, dickkopf WNT signaling pathway inhibitor 3; CDO1, cysteine dioxygenase type 1; TXNIP, thioredoxin interacting protein*.

![Forest plot of three known prognosis biomarkers.](fonc-10-00315-g0001){#F1}

Discovering Potential Biomarkers for EAC in OSeac
-------------------------------------------------

In addition, to further test the prediction power of OSeac, we choose a known prognostic marker of gastric cancer (GC) ([@B24]) to analyze it in OSeac. We examined prognostic potency of *RAP1B* for EAC patients by OSeac, and found that *RAP1B* was significantly associated with unfavorable OS in TCGA (*P* = 0.0464, HR: 2.0045, 95% CI: 1.0111--3.9741), GSE13898 (*P* = 0.0241, HR: 3.0920, 95% CI: 1.1596--8.2446) and GSE19417 (*P* = 0.0138, HR: 2.4119, 95% CI: 1.1965--4.8618). This suggests that *RAP1B* could be a potential prognostic indicator of poor OS for EAC ([Figure 2](#F2){ref-type="fig"}).
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Discussion {#s4}
==========

In this study, we have developed an online tool OSeac to analyze prognostic biomarkers in EAC. As most researchers may concern the accuracy rate and potential error from OSeac, for example, we performed the prognosis analysis for one gene each time in OSeac, the gene will be regarded significant for prognosis when *P*-value is \< 0.05, while there are more than 20,000 genes in human genome, which means we may get 1,000 significant prognostic genes by chance when we do genome-wide repeated measurements. In addition, the EAC expression datasets may come from different analyzing platforms/technologies, or from different ethnicities, all these may influence the results of prognosis analysis. Nevertheless, in order to increase the specificity of prognosis biomarkers, we did our best to collect EAC expression datasets from GEO, TCGA and literatures as many as possible, and offered the opportunities to do independent validation across different EAC cohorts, which as we know is most important for biomarker development. Finally, to determine the performance of OSeac, three published EAC prognostic biomarkers were assessed in OSeac, and all of them reach statistical significance for prognosis in OSeac as expected, indicating the good performance of OSeac in prognostic biomarker screening. OSeac could also be used to screen novel prognosis biomarker for EAC, for example, *RAP1B* contributes to tumor malignant behavior and poor prognosis in GC ([@B24]). Using OSeac to assess the prognostic value of *RAP1B* in EAC, we found that *RAP1B* is a potential unfavorable prognostic indicator for EAC patients.

In conclusion, OSeac could help clinicians, biologists, and researchers to easily evaluate prognostic significance of genes of interests in EAC. The limitation of OSeac is that currently OSeac contains only 3 datasets and 198 samples, the sample number is relatively low, therefore, we will keep update and expand OSeac when new EAC datasets are available.
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